Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 13/20 | 0.39 |
| ▸ | FEN1 | P39748 | 13/20 | 0.39 |
| ▸ | OXTR | P30559 | 3/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.32 |
| ▸ | FYN | P06241 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23980125 | 0.81 | OXTR (0.39) | ALOX5APFEN1OXTRAVPR2AVPR1A | |
| SCHEMBL30260513 | 0.79 | ALOX5AP (0.40) | ALOX5APFEN1PDCD1CD274 | |
| SCHEMBL29686208 | 0.77 | FEN1 (0.44) | ALOX5APFEN1PDCD1CD274 | |
| SCHEMBL24498032 | 0.77 | FEN1 (0.44) | ALOX5APFEN1PDCD1CD274 | |
| SCHEMBL24498490 | 0.74 | ALOX5AP (0.43) | ALOX5APFEN1FYN | |
| SCHEMBL23980561 | 0.74 | OXTR (0.49) | ALOX5APFEN1OXTRAVPR2AVPR1A | |
| SCHEMBL31106622 | 0.73 | ALOX5AP (0.49) | ALOX5APFEN1FYN | |
| SCHEMBL23980129 | 0.72 | TYK2 (0.44) | ALOX5APFEN1PDCD1CD274FYN | |
| SCHEMBL30260594 | 0.69 | CD274 (0.35) | ALOX5APFEN1PDCD1CD274FYN | |
| SCHEMBL24498473 | 0.69 | TYK2 (0.41) | ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | JAK3, TYK2, IRAK3 | ALOX5AP 3774/4885FEN1 3472/4885OXTR 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.